Investment
Features
FeesSafety
Academy
More
Pluang+

Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Company Fundamentals
19 Oct 2026
Na
View Source
Neutral
Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its share capital. This program is designed to enhance shareholder value and is conducted in compliance with EU market regulations. The buyback continues until the maximum value of DKK 3 billion is reached or the program ends in January 2027.

Jyske Bank's share repurchase program is ongoing with DKK 2.15 billion spent on buybacks so far. For readers following Financials-sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:41 WIB: out of 142 priced stocks, 117 rose and 22 fell. Notable movers include AIG at USD 80.22 with a 3.60% increase and a typical hold time of 72 days on Pluang.

More News

Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...

Company Fundamentals
Bullish
16 minutes ago
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...

Market News
Bullish
1 hour ago
Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...

Market News
Bullish
1 hour ago
Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...

Market News
Bullish
2 hours ago
Red Cat offers €39/share to acquire Steyr Motors, boosting its maritime defense tech and Austrian growth.

Red Cat offers €39/share to acquire Steyr Motors, boosting its maritime defense tech and Austrian growth.

Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App